NIDB 3002
Alternative Names: NIDB-3002Latest Information Update: 15 Feb 2023
At a glance
- Originator Discoveric Bio; Light Chain Bioscience
- Class Antibacterials; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Gram-negative infections
Most Recent Events
- 15 Feb 2023 Feedback incorporated
- 04 Jan 2023 NIDB 3002 is available for licensing as of 04 Jan 2023. https://www.discovericbio.com/partner-with-us/partner-with-us.html
- 04 Jan 2023 Early research in Gram-negative infections in Switzerland (Parenteral) (Discoveric bio pipeline, January 2023)